Incidence of serious adverse events (safety);All-cause mortality at 29 and 60 days;SARS-CoV-2 viral load as assessed using various sample types;Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital;Incidence of laboratory abnormalities (safety);Anti-drug antibodies;Incidence of adverse events (safety);Incidence of dose-limiting toxicities (safety);Incidence of treatment-emergent adverse events (safety);Cytokine levels

Incidence of serious adverse events (safety);All-cause mortality at 29 and 60 days;SARS-CoV-2 viral load as assessed using various sample types;Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital;Incidence of laboratory abnormalities (safety);Anti-drug antibodies;Incidence of adverse events (safety);Incidence of dose-limiting toxicities (safety);Incidence of treatment-emergent adverse events (safety);Cytokine levels